Document:

Unassociated Document

    Exhibit
10.1

     

    RETIREMENT
AGREEMENT

     

    This Retirement Agreement (“Agreement”)
is entered into as of July 1, 2010 (“Effective Date”), by and between Conmed
Healthcare Management, Inc., a Maryland corporation (the “Company”), and Howard
M. Haft, M.D. (“Dr. Haft”).

     

    WHEREAS, the parties have previously
entered into that certain Employment Agreement dated as of January 26, 2007;
and

     

    WHEREAS, except as otherwise expressly
provided herein, and except with respect to  Paragraphs 5.2(c) and
(c)(i), (c)(ii), and (c)(iii), (d), (e) and (f) of the January 26, 2007
Agreement (relating to period of non-competition, non-solicitation, and
non-defamation, and remedies therefor), the January 26, 2007 Employment
Agreement is being terminated and this Retirement Agreement is intended to
substitute therefor.

     

    In consideration of the mutual
covenants and conditions set forth herein, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereby agree as follows:

     

    1.           Employment.  (a)  Employment.  For
the period July 1, 2010 through August 31, 2010, the Company hereby employs Dr.
Haft in the capacity of Chief Medical Officer of the Company, reporting directly
to the President and Chief Executive Officer of the Company.  Dr. Haft
accepts such employment and agrees to perform such roles and provide such
management and other services for the Company as are customary to such office
and such additional responsibilities, consistent with his position as the Chief
Medical Officer, as may be assigned to him from time to time by the President
and Chief Executive Officer of the Company.  Employee shall be
entitled to all salary and other benefits under the January 26, 2007 Employment
Agreement during this two (2) month term. At the conclusion of this period, Dr.
Haft shall surrender to the Company the corporate credit card currently assigned
and shall obtain reimbursement for further expenses in accordance with Paragraph
4.3, below.

     

    (b)  Retirement.  For
the period September 1, 2010 through February 28, 2011 (the “Term”), the Company
shall pay Dr. Haft the total sum of $125,000 (“Retirement
Payment”).  The Retirement Payment shall be paid in installments
either every two weeks or twice per month based on and in accordance with the
Company’s regular payroll procedures, during the Term. Said payments shall be
treated as compensation with appropriate withholding and a Form W-2 issued for
the corresponding tax years. Additionally, said payments shall be conditioned
upon execution of the Release previously negotiated and agreed and attached to
the Employment Agreement as Exhibit A, except that Conmed, Inc. shall be
substituted for PACE Health Management Systems, Inc. as the named party
therein.

     

    2.           Independent
Contractor.  Beginning September 1, 2010 until terminated in
accordance with Section 5 hereof, Dr. Haft shall be retained as an independent
contractor.  Dr. Haft agrees to perform such roles and provide such
services for the Company, if any, as the Company may reasonably assign to him
from time to time by the President and Chief Executive Officer of the
Company.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    3.           Obligation for Co-operation in
Litigation.  Dr. Haft agrees that so long as this Agreement
remains in effect, he shall co-operate fully in conjunction with the defense of
any litigation against the Company, any of its employees, and any of the
governmental entities to whom the Company provides healthcare services relating
to the rendering of healthcare services or the management/supervision of
healthcare personnel. Dr Haft will be compensated as an Independent contractor
as specified  herein for his participation and
cooperation.

     

    4.           Compensation and Benefits as
Independent Contractor.

     

    4.1           Cash
Compensation.  For the performance of Dr. Haft’s duties
hereunder as an Independent Contractor, the Company shall pay Dr. Haft the total
sum of $1,200 per day or portion of a day (“I.C. Payments”).  The I.C.
Payments shall be paid in installments either every two weeks or twice per
month, based on and in accordance with Company’s regular payroll procedures,
during the Term. The parties agree that the compensation under this Paragraph
shall be in addition to the Retirement Payment under Paragraph 1.b. above.
However, taxes shall be withheld and reporting shall be made consistent with the
Retirement Payments despite referral to the status herein as “Independent
Contractor.”

     

    4.2           Bonus Plan.

     

    (a)           During
the period January 1, 2010 through August 31, 2010, Dr. Haft shall be entitled
to continued participation in the bonus compensation plan further defined in
Section 3.2(b).  Any bonus or incentive compensation paid to Dr. Haft
shall be in addition to Salary and Retirement Payment.  All
compensation earned by Dr. Haft, including any bonus as an employee, shall be
subject to all applicable state and federal tax obligations.  Dr. Haft
shall be solely responsible for all applicable state and federal tax obligations
for the I.C. Payments.

     

    (b)           Dr.
Haft shall be eligible annually for a bonus to be approved by the
Board.  The amount of the bonus shall be equal to a value of up to 20%
of Dr. Haft’s total compensation paid by Company during the period January 1,
2010 through August 31, 2010.  Dr. Haft’s bonus, as earned, shall be
payable in the form of cash and/or shares of the Company’s capital stock issued
by the Company, as shall be determined in the sole discretion of the Board, at
the later of (i) the end of the first fiscal quarter of the Company following
the end of the period for which the bonus was earned, or (ii) upon the issuance
of the independent auditors report for the period ending when the bonus was
earned.

     

    4.3           Reimbursement of Expenses as an
Independent Contractor.  Dr. Haft shall be entitled to be
reimbursed for all reasonable expenses as described in accordance with Company
policy, including but not limited to expenses for travel for business, as
appropriate, and business meals and entertainment, incurred by Dr. Haft in
performing his tasks, duties and responsibilities under Sections 2, or otherwise
as approved in advance by the Company in connection with and reasonably related
to the furtherance of the Company’s business.  The Company shall
reimburse Dr. Haft for travel expenses for approved or assigned business
purposes, including but not limited to, tolls, gasoline and
parking.  Dr. Haft shall submit expense reports and receipts
documenting the expenses incurred in accordance with Company policy, and the
Company shall remit payment in accordance with its ordinary procedures through
its payroll process.  The Company’s obligation to reimburse authorized
expenses incurred or accrued prior to termination of Dr. Haft’s service as an
independent contractor hereunder, whether by the Company with or without Cause
or by Dr. Haft with or without Good Reason (“Cause”, “without Cause” and “Good
Reason” are defined in Section 5.1 of the original Employment Agreement and
those definitions are incorporated herein), shall survive any such
termination.

     

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

       

    

    4.4           Additional Benefits During period of
Service as Independent Contractor.  Dr. Haft shall be permitted
to retain at Company expense the Blackberry currently in his possession for use
during his term of service as an independent contractor. Dr. Haft shall also be
permitted to retain the laptop computer currently in his possession during the
period of service as an independent contractor. Further, in exchange for Dr.
Haft maintaining his license(s) to practice medicine, the Company agrees to
maintain the cost of such licensure(s) and shall include Dr. Haft on the Conmed
Malpractice Insurance coverage.

     

    4.5           Continuation of Life Insurance.
As provided in Paragraph 3.4 of the Employment Agreement, the Company
shall continue in force and effect for six months from September 1, 2010 any
life insurance benefits to which Dr. Haft was entitled in his role as Chief
Medical Officer.

     

    5.           Termination.  Either
party may terminate the independent contractor arrangement with 30 days’ written
notice to the other.

     

    6.           Non-Disclosure.  Dr.
Haft agrees to execute the confidentiality Agreement attached as Exhibit B with
respect to confidential information of the Company and to abide by its
terms.

     

    7.           General
Provisions

     

    7.1           Assignment.  Neither
party may assign or delegate any of his or its rights or obligations under this
Agreement without the prior written consent of the other party.

     

    7.2           Entire
Agreement.  This Agreement contains the entire agreement
between the parties with respect to the subject matter hereof and supersedes any
and all prior written and verbal agreements between the parties.

     

    7.3           Modifications.  This
Agreement may be changed or modified only by an agreement in writing signed by
both parties hereto.

     

    7.4           Successors and
Assigns.  The provisions of this Agreement shall inure to the
benefit of, and be binding upon, the Company and its successors and permitted
assigns and Dr. Haft and Dr. Haft’s legal representatives, heirs, legatees,
distributees, assigns and transferees by operation of law, whether or not any
such person shall have become a party to this Agreement and have agreed in
writing to join and be bound by the terms and conditions hereof.

     

    7.5           Governing Law.  This
Agreement shall be governed by, construed and enforced in accordance with, the
laws of the State of Maryland, and venue and jurisdiction for any disputes
hereunder shall be heard in any court of competent jurisdiction in Maryland for
all purposes.

     

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

       

    

    7.6           Severability.  If
any provision of this Agreement is held by a court of competent jurisdiction to
be invalid, void or unenforceable, the remaining provisions shall nevertheless
continue in full force and effect.

     

    7.7           Further
Assurances.  The parties will execute such further instruments
and take such further actions as may be reasonably necessary to carry out the
intent of this Agreement.

     

    7.8           Notices.  Any
notices or other communications required or permitted hereunder shall be in
writing and shall be deemed received by the recipient when delivered personally
or, if mailed, five (5) days after the date of deposit in the United States
mail, certified or registered, postage prepaid and addressed, in the case of the
Company, to its corporate headquarters, attention Chairman of the Board, and in
the case of Dr. Haft, to the address shown for Dr. Haft on the signature page
hereof, or to such other address as either party may later specify by at least
ten (10) days advance written notice delivered to the other party in accordance
herewith.

     

    7.9           No Waiver.  The
failure of either party to enforce any provision of this Agreement shall not be
construed as a waiver of that provision, nor prevent that party thereafter from
enforcing that provision of any other provision of this Agreement.

     

    7.10           Legal Fees and
Expenses.  In the event of any disputes under this Agreement,
the prevailing party or parties shall be reimbursed by the party or parties who
do not prevail for their reasonable attorneys, accountants and expert fees and
related expenses and for the costs of such proceeding.

     

    7.11           Counterparts.  This
Agreement may be executed by exchange of facsimile signature pages and/or in
counterparts, each of which shall be deemed to be an original, but all of which
together shall constitute one and the same instrument.

     

    (Remainder
of page intentionally left blank)

     

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

     

    IN
WITNESS WHEREOF, the Company and Dr. Haft have executed this Agreement,
effective as of the day and year first above written.

    

    

    CONMED
HEALTHCARE MANAGEMENT, INC.

    

    

    

    By: 
/s/ Richard W.
Turner

    Richard
W. Turner, Ph.D., Chairman and CEO

    

    Address:

    7250
Parkway Dr.

    Hanover,
MD 21076

    

    

    By: /s/ Howard M. Haft

    Howard M.
Haft, M.D.

    

    Address:

    208
Morgans Ridge Court

    LaPlata,
MD 20646-3100Unassociated Document

    
       

    

    
      
        
          
            
              
                
                  
                    
                      
                        	 	 	 	 	 
	 
      	 
      	
                                Confidential Materials omitted and filed separately with the

                              	 
      	 
      
	 
      	 
      	
                                Securities and Exchange Commission. Asterisks denote omissions.

                              	 
      	 
      
	 
      	 
      	 
      	 
      	
                                Exhibit 10.1

                              

                      

                    

                  

                

              

            

          

        

      

    

    

    May 7,
2007 

    SUPPLY
AGREEMENT

    

    
      
        
          	
                  Moss,
      Inc.

                	
                  IDEXX
      Operations, Inc.

                
	
                  P.O.
      Box 189

                	
                  One
      IDEXX Drive

                
	
                  Pasadena,
      MD  21123-0189

                	
                  Westbrook,
      ME  04092

                
	
                  (“Moss”)

                	
                  (“IDEXX”)

                

        

      

    

    

    IDEXX
desires to purchase from Moss certain chromogen substrates to be incorporated
into various of IDEXX’s veterinary diagnostic products.  Moss hereby
agrees to provide IDEXX with such chromogen substrates described below in such
quantities as IDEXX may order from time to time on the following terms and
conditions:

    

    
      	
              PRODUCTS:

            	
              The
      chromogen substrates described and in conformity with the specifications
      on Schedule
      A (the “Products”).  This
      Agreement and Schedule A may
      only be amended by the parties’ mutual agreement.  The parties
      acknowledge that the terms and conditions of this Agreement and the
      quantities of the Products purchased by IDEXX hereunder shall be treated
      as confidential information pursuant to the confidential disclosure
      agreements previously entered into by the parties on March 1,
      2001.

            

    

    

    
      	
              PRICING:

            	
              As
      set forth on Schedule
      B.  Prices are fixed through 31 December
      2008.  Thereafter, Moss shall notify IDEXX in writing at least
      120 days before each subsequent calendar year of any changes in the prices
      of Products; provided,
      however, that in no event shall Moss increase prices in any given
      calendar year greater than [**]%.

            

    

    

    Payment
terms shall be net thirty (30) from the date IDEXX receives Moss’
invoice.

    

    
      	
              SHIPPING:

            	
              Shipping
      terms are F.O.B. Moss’ facility in Hanover, Maryland.  Title to
      and risk of loss for Products shall pass to IDEXX upon delivery to the
      carrier (specified by IDEXX) at Moss’ facility in Hanover,
      Maryland.  Moss shall cooperate with IDEXX in the documentation
      and proof of loss claims presented by IDEXX to the appropriate carrier
      and/or insurer.

            

    

    

    Moss
shall pack and ship Products in the manner described on Schedule A, and
otherwise consistent with Moss’ usual practices, which shall be at least
reasonably satisfactory to ensure that the Products are received by IDEXX
undamaged.  Costs of packing are included in the Prices set forth on
Schedule
B.

    

    
      SPECIFICATIONS

    

    
      	
              AND
      VALIDATION:

            	
              As
      set forth on Schedule A, as
      may be amended from time to time by the parties’ mutual
      agreement.

            

    

    

    
      	 	
              Moss
      shall not change the specifications attached hereto as Schedule A,
      without Moss providing IDEXX at least 12 months’ prior written notice (any
      such notice, a "Products Change
      Notice"), unless a shorter time frame can be mutually agreed, in
      order to permit IDEXX to evaluate such proposals and to verify that
      regulatory, performance and quality criteria will be
      satisfied.  IDEXX shall have the right to approve or disapprove
      all proposed changes before the incorporation of such changes into the
      Products.  In the course of IDEXX’s evaluation of such change,
      IDEXX shall promptly notify Moss of any test result that indicates such
      change will fail to meet any such criteria.  Upon written
      approval by IDEXX of changes in the specifications described in a Products
      Change Notice, the approved changes shall be deemed to be incorporated in
      Schedule
      A.

            

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    
      	
              QUALITY:

            	
              In
      order to ensure quality and resolve any issues that may arise with the
      Products, Moss shall permit IDEXX access to Moss’ facilities as described
      in Schedule
      C.

            

    

    

    
      	
              ORDERS:

            	
              IDEXX
      shall order Products from Moss by written purchase orders ("Orders"),
      stating the number of Products ordered , one or more scheduled delivery
      dates (which shall be not less than 30 days after order date), and one or
      more delivery destinations.  Each Order shall be accompanied by
      the then current version of the agreed specifications.  Moss
      shall accept and fill all Orders for Products placed under this Agreement
      that specify delivery dates within the Term and that conform to the
      preceding sentence and acknowledge such acceptance in writing within 5
      days after receipt of the Order.

            

    

    

    [**].

    

    
      	
              FORECASTS:

            	
              IDEXX
      shall furnish to Moss not less than 30 days before the commencement of
      each calendar quarter during the term of this Agreement a forecast of the
      quantity of the Products for which IDEXX expects to submit Orders in such
      calendar quarter and the three succeeding calendar
      quarters.  Each such forecast after the first shall update and
      replace prior forecasts as to the calendar quarters covered by such prior
      forecasts.  It is understood that such forecasts are merely
      estimates and are not to be considered
Orders.

            

    

    

    
      LOT
ACCEPTANCE:

    

    

    A.            As soon as such is available, Moss shall ship to IDEXX a
sample (the "Sample") of each manufacturing lot from which an order of
[**] (Part Nos.: 23-08303-00 and 23-01788-00) is
to be filled.  All quantities represented by the Sample shall be
included in any invoice that Moss provides to IDEXX relating to such lot of
Products.  IDEXX shall use such Sample for the purpose of subjecting
it to inspection and performance testing.  IDEXX shall have a maximum
of [**] business days from receipt of a Sample to complete such
testing and notify Moss in writing of acceptance or rejection of the Sample.  If IDEXX does not deliver such
written notice to Moss within such [**] business day period, Moss shall be authorized to ship
the Product in accordance with the Orders. If IDEXX notifies Moss that IDEXX has
rejected the Sample, Moss shall, within twenty business days, replace the
rejected Product and submit a new Sample to IDEXX for testing.

    

    B.            Moss
shall perform the in-process Product inspection and testing procedures developed pursuant to Schedule C to this Agreement
on the [**] Products (Part Nos.:
02-07209-00, 02-07701-00 and 02-07510-00) ordered by IDEXX.  Before
shipping any Product, Moss shall supply IDEXX with documentary evidence of such
testing and the results thereof in the format agreed upon by the parties
pursuant to Schedule C.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    
      	
              TERM:

            	
              The
      date of this Agreement through termination by either party by providing
      written notice of termination not less than 24 months’ prior to the
      effective date of such termination.

            

    

    

    
      	
              ESCROW:

            	
              Moss
      hereby agrees to deposit copies of
      Moss’ manufacturing information relating to the Products (as such
      documentation currently exists) with Iron Mountain Intellectual Property
      Management, Inc. (the “Escrow Agent”) for the Escrow Agent to keep in
      confidence and to be released to IDEXX solely upon the occurrence of
      certain triggering events as more particularly described
      below.  Moss further agrees to update its deposit of such
      information from time to time as required so that the information on
      deposit with the Escrow Agent is complete, current and
      accurate.  Upon Moss depositing its manufacturing information
      with the Escrow Agent, or upon Moss’ updating of such manufacturing
      information thereafter, IDEXX’s operations manufacturing manager,
      technical support manager or quality support manager ([**]) shall have the
      opportunity to review such manufacturing information to verify that such
      information is in a form that would allow IDEXX to use such information to
      manufacture the Products upon the occurrence of one of the triggering
      events discussed below.  Prior to its review of any
      manufacturing information (either upon initial deposit or the updating of
      such information), IDEXX shall provide Moss with the name of the person
      who shall conduct such review.  Representatives from Moss shall
      have the right and opportunity to be present for the duration of such
      review.  Following such review, Moss’ manufacturing documents
      shall be immediately placed in the possession of the Escrow Agent and
      shall not be viewed again by anyone at IDEXX unless and until the
      occurrence of one of the triggering events listed
  below.

            

    

    

    IDEXX and
Moss agree that the Escrow Agent shall be only be permitted to release Moss’
manufacturing documents to IDEXX upon the occurrence of one of the following
triggering events: (i) Moss or a successor in interest to Moss by merger, by
operation of law, assignment, purchase or otherwise, ceases to provide the
Products to IDEXX, (ii) Moss has a receiver, administrator or liquidator
appointed to the whole or any substantial part of its assets or if an order is
made or a resolution passed for the winding up of Moss which is not revoked
within thirty (30) days, (iii)  Moss fails, for any reason, including on
account of an event of force majeure as described below, to deliver on a timely
basis all quantities of Products ordered pursuant to one or more valid orders
placed in compliance with the terms of this Agreement, which failure continues
for a period of [**] days; (iv) Moss fails, for any reason, including an
event of force majeure, to deliver Products which conform to the applicable
specifications, which failure is not corrected within [**] days after notice
thereof; or (v) any other event occurs, including an event of force
majeure, which renders Moss incapable of supplying Product to IDEXX pursuant to
this Agreement if it reasonably foreseeable that such inability shall continue
for [**] days or more.  Upon the occurrence of any of the triggering
events described above, IDEXX agrees to use Moss’ manufacturing information only
for its own internal purposes and to utilize strict security measures to keep
such information confidential.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    In the
event that a triggering event occurs and IDEXX commences manufacture of the
Products as set forth above, IDEXX shall pay Moss a royalty of [**]% of the
price per Product set forth on Schedule
B.  Further, in the event that a triggering event occurs and
IDEXX commences manufacture of the Products as set forth above, Moss shall make
its employees available to IDEXX, at IDEXX’s expense, to assist IDEXX with its
commencement of manufacturing the Product, under the condition that those Moss
employees are not involved in manufacturing the Products at Moss’s
facilities.  If and when Moss regains its ability to manufacture
IDEXX’s requirements of the Products, IDEXX shall cease manufacturing the
Products for itself, shall destroy all copies of such manufacturing documents
(whether in hard copy or electronic form) and shall return Moss’ original
manufacturing documents into escrow with the Escrow Agent and provide Moss with
written certification that it has done so.  In addition, if and when
Moss regains its ability to manufacture IDEXX’s requirements of the Products,
Moss shall purchase from IDEXX, at cost, all of the unused raw materials that
IDEXX purchased to manufacture the Products, provided however that Moss shall
not be required to purchase any amounts of raw materials in excess of those
necessary to create [**] liters of the
Product.  All unused raw materials that are purchased by Moss from
IDEXX must meet Moss’s raw materials specifications.  If the raw
materials to be purchased do not meet Moss’s specifications, Moss will not be
required to purchase such raw materials.

    

    Upon
termination or expiration of this Agreement, the Escrow Agent shall return all
of Moss’ manufacturing documents to Moss, or at Moss’ request, the Escrow Agent
shall destroy such information and certify to Moss in writing that it has done
so.

    

    
      	
              WARRANTY:

            	
              Moss
      warrants to IDEXX that it shall produce the Products in conformity to the
      specifications set forth on the attached Schedule
      A.  In the event that any Products delivered to IDEXX do
      not, conform to such specifications, Moss agrees to replace such Products
      at no cost to IDEXX.

            

    

    

    Throughout
the term of this Agreement, Moss shall maintain commercial general liability
insurance covering Moss’activities under this Agreement, with a coverage limit
of not less than US $[**] million Moss shall provide IDEXX with a
certificate evidencing its respective insurance coverages as IDEXX shall request
from time to time.

    

    
      	
              MISCELLANEOUS:

            	
              This
      Agreement shall be governed by the laws of the State of (Maryland) and
      cannot be modified except in writing signed by authorized representatives
      of both parties.

            

    

    

    This
Agreement, which includes the confidential disclosure agreements previously
signed by the parties on March 1, 2001 (the term of which extends through 2026
and which is unaffected by this Agreement) constitutes the entire agreement
between the parties with respect to the subject matter hereof and, other than as
set forth herein to the contrary, supersedes all prior agreements and
negotiations relating to the subject matter hereof.

    

    Any term
or condition set forth in any document provided by either party to the other,
included IDEXX’s terms and conditions of purchase and Moss’ terms and conditions
of sale, which is in any way different from, inconsistent with or in addition to
the terms and conditions set forth herein will not become a part of this
Agreement or be binding on either party.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    Each
party to this Agreement shall comply with all applicable laws and regulations
relating to the Products and their respective performance under this
Agreement.

    

    Neither
party may assign this Agreement or any of the rights or obligations hereunder,
or subcontract performance, without the prior written consent of the other
party, except that either party may assign this Agreement to any affiliate, or
to any person or entity that acquires all or substantially all of such party’s
assets or business, provided that any such successor or assignee agrees to
perform and assume such party’s duties under this Agreement.

    

    If any
provision of this Agreement is held by a court of competent jurisdiction to be
unenforceable because it is invalid or in conflict with any law of any relevant
jurisdiction, the validity of the remaining provisions shall not be
affected.

    

    Any
controversy or claim arising out of or relating to this agreement, or the breach
thereof, shall be settled by arbitration conducted in the state of
Maryland and administered by the American Arbitration Association under its
Commercial Arbitration Rules, and judgment on the award rendered by the
arbitrator(s) may be entered in any court having jurisdiction
thereof.

    

    The
waiver by either party of a breach or a default of any provision of this
Agreement by the other party shall not be construed as a waiver of any
succeeding breach or default of the same or any other provision, nor shall any
delay or omission on the part of either party to exercise or avail itself of any
right, power or privilege that it has or may have hereunder operated as a waiver
of any right, power or privilege by such party.

    

    Please
indicate your acceptance of this Agreement by signing one copy and returning it
to the address above:

    

    
      
        
          	
                  MOSS, INC.

                	 
      	
                  IDEXX OPERATIONS, INC.

                	 
      
	 
      	 
      	 
      	 
      
	
                  /s/ Richard L. Guertin

                	 
      	
                  /s/ Jon Ayers

                	 
      
	 
      	 
      	 
      	 
      
	
                  Name:

                	
                  Richard L. Guertin

                	 
      	
                  Name:

                	
                  Jon Ayers

                	 
      
	
                  Title:

                	
                  Chairman and CEO

                	 
      	
                  Title:

                	
                  Chairman, President and CEO

                	 
      

        

      

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    SCHEDULE
A

    

    Products Description and
Specifications

    

    General Products
Description:

    

    
      	
              23-08303-00

            	
              one
      part [**] substrate specifically
      for [**]

            

    

    
      	
              23-01788-00

            	
              one
      part [**] substrate specifically for
[**]

            

    

    
      	
              02-07209-00

            	
              [**]
      one part substrate for use in [**]

            

    

    
      	
              02-07701-00

            	
              [**]
      one part substrate for use in [**]

            

    

    
      	
              02-07510-00

            	
              [**]
      substrate for alkaline phosphatase

            

    

    

    Products
Specifications:

    

    See attached.

    

    [**]

    

    A total
of eight pages were omitted and filed separately with the Securities and
Exchange Commission pursuant to a request for confidential
treatment.

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

    

    SCHEDULE
B

    

    Price and
Packaging

    

    2006 Per-Product
Price:

    

    
      	
              23-08303-00

            	
              $[**]/Lt
      with a minimum order of [**] liters

            

    

    
      	
              23-01788-00

            	
              $[**]/Lt
      with a minimum order of [**] liters

            

    

    
      	
              02-07209-00

            	
              $[**]/[**]
      ml bottle minimum order of [**]
bottles

            

    

    
      	
              02-07701-00

            	
              $[**]/[**]
      ml bottle minimum order of [**]
bottles

            

    

    
      	
              02-07510-00

            	
              $[**]/[**]
      ml fill minimum order of [**]
bottles

            

    

    

    
      2007 and 2008 Per-Product
Price:

    

    

    
      	
              23-08303-00

            	
              $[**]/Lt
      with a minimum order of [**] liters

            

    

    
      	
              23-01788-00

            	
              $[**]/Lt
      with a minimum order of [**] liters

            

    

    
      	
              02-07209-00

            	
              $[**]/[**]
      ml bottle minimum order of [**]
bottles

            

    

    
      	
              02-07701-00

            	
              $[**]/[**]
      ml bottle minimum order of [**]
bottles

            

    

    
      	
              02-07510-00

            	
              $[**]/[**]
      ml fill minimum order of [**]
bottles

            

    

    

    
      Packaging:

    

    
      	
              23-08303-00

            	
              sample;
      [**] Lt cubitainer, minimum [**] liter fill.  Bulk; [**] Lt
      cubitainer

            

    

    
      	
              23-01788-00

            	
              sample;
      [**] Lt cubitainer, minimum [**] liter fill.  Bulk; [**] Lt
      cubitainer

            

    

    
      	
              02-07209-00

            	
              Brown,
      polyethylene [**] ml bottle,
unlabeled

            

    

    
      	
              02-07701-00

            	
              Brown,
      polyethylene [**] ml bottle,
unlabeled

            

    

    
      	
              02-07510-00

            	
              Brown,
      polyethylene [**] ml bottle,
unlabeled

            

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    SCHEDULE
C

    

    Validation, In-process
Testing, IDEXX Test and Acceptance and Facility Access

    

    In-process
Testing:

    

    IDEXX and
Moss  have agreed to the Product Control Plan set forth at Schedule D which
shall document the in-process control strategy for on-going specification
compliance.  The Product Control Plan shall be revision
controlled.  The parties may agree to changes to the Product Control
Plan from time to time to ensure quality of Products and conformity with
applicable specifications, and otherwise as new monitoring methodologies become
available or new standards are generally adopted in the
industry.  Each revision of the Product Control Plan shall be dated
and approved in writing by IDEXX and Moss.

    

    IDEXX Access to Moss
Facilities:

    

    In the
event that IDEXX experiences recurring, emergent defects or anomalies in the
IDEXX products in which the Products are incorporated, the proper investigation
of which warrants and necessitates raw material root cause evaluation by IDEXX,
Moss shall grant IDEXX access to its US manufacturing facility or facilities
that manufacture the Products (“Facilities”) for the
purpose of auditing Moss’ processes and quality to discover any such quality or
process issues.  Such IDEXX access by Moss shall be subject to the
following limitations:

    

    
      	
               
      

            	
              a)

            	
              The
      date and time of such access shall be mutually agreed upon with at least 2
      weeks prior notice and shall take place within Moss’ normal business
      hours;

            

    

    

    
      	
               
      

            	
              b)

            	
              IDEXX
      shall present Moss with the name(s) of personnel visiting which shall be
      limited to 3 or less individuals per
visit;

            

    

    

    
      	
               
      

            	
              c)

            	
              IDEXX’s
      access to Moss’ Facilities is for the purpose of, and limited to,
      discussions and consultation regarding any root cause analysis or to
      expedite any delivery or quality issues, and shall not be for the
      purpose of in-process inspections by IDEXX;
and

            

    

    

    
      	
               
      

            	
              d)

            	
              All
      personnel visiting shall (i) be bound by the terms of this agreement, (ii)
      be bound by the confidential disclosure agreements previously executed by
      IDEXX and Moss, and (iii) comply with MOSS' safety and security
      policies.

            

    

     

    
      
         

      

      
         

        
          

        

      

      
         

      

    

     

    SCHEDULE
D

    

    Product Control
Plan

    

    See
attached.

    

    [**]

    

    A total of three pages were
omitted and filed separately with the Securities and Exchange Commission
pursuant to a request for confidential treatment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00176-of-00352.parquet"}]]